Bio-Path Holdings, Inc. (BPTH)

2,6600 -0,1000 (-3,62%) Börsenschluss: 04:00PM EDT

Bio-Path Holdings, Inc.

4710 Bellaire Boulevard
Suite 210
Bellaire, TX 77401
United States
832 742 1357
https://www.biopathholdings.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 10

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Peter H. Nielsen MBA	Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer	696,24k	N/A	1949
Mr. Douglas P. Morris	Co-Founder, Director of Investor Relations, Secretary & Director	73,74k	N/A	1956
Mr. Michael Hickey M.B.A.	VP of Clinical Operations	N/A	N/A	N/A
Mr. Anthony Price	Senior Vice President of Finance, Accounting & Administration	N/A	N/A	N/A
Dr. Ana Tari Ashizawa M.B.A., MBA, Ph.D.	Senior Vice President of Research, Development & Clinical Design	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Corporate Governance

Bio-Path Holdings, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.